Reviva Pharma Seeks Share Increase, Reverse Split Ahead of Key Vote

Ticker: RVPH · Form: DEF 14A · Filed: Nov 4, 2025

Sentiment: bearish

Topics: Proxy Statement, Reverse Stock Split, Authorized Shares Increase, Executive Compensation, Corporate Governance, Shareholder Vote, Biotechnology

Related Tickers: RVPH

TL;DR

**RVPH is gearing up for a reverse split and massive share authorization increase, signaling potential dilution and a desperate attempt to stay listed.**

AI Summary

REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) is holding its Annual Meeting on December 18, 2025, where stockholders will vote on several critical proposals. Key among these is the election of five director nominees and the ratification of Baker Tilly US, LLP as the independent auditor for 2025. The company is also seeking advisory approval for executive compensation. Financially, RVPH proposes to increase its authorized shares of common stock from 315,000,000 to 515,000,000, a 63.5% increase, and to implement a reverse stock split at a ratio between 1-for-2 and 1-for-20. These actions are strategic moves to potentially improve stock price and provide flexibility for future capital raises or acquisitions. The filing also details the 2024 Summary Compensation Table for named executive officers and outlines the company's corporate governance structure, including board composition and risk oversight. The company's strategic outlook appears focused on maintaining NASDAQ listing compliance and enhancing financial flexibility.

Why It Matters

This DEF 14A filing is crucial for RVPH investors as it outlines proposals that could significantly impact share structure and valuation. The proposed increase in authorized shares to 515,000,000 and a potential reverse stock split (1:2 to 1:20) are often precursors to capital raises or efforts to meet exchange listing requirements, directly affecting existing shareholders' equity and per-share metrics. For employees, the executive compensation vote and director elections reflect governance stability. In a competitive biotech landscape, these financial maneuvers are vital for RVPH to fund ongoing research and development, potentially impacting future drug pipelines and market position.

Risk Assessment

Risk Level: high — The proposal to increase authorized shares by 63.5% from 315,000,000 to 515,000,000, coupled with a potential reverse stock split ranging from 1-for-2 to 1-for-20, indicates significant dilution risk and potential NASDAQ delisting concerns. These actions are often taken by companies with low stock prices to avoid delisting and facilitate future capital raises, which could further dilute existing shareholders.

Analyst Insight

Investors should vote against the increase in authorized shares and the reverse stock split if they are concerned about dilution and the potential for further capital raises at depressed valuations. Consider the implications of these proposals on your current holdings and the company's long-term financial health before casting your vote.

Financial Highlights

debt To Equity
0.0
revenue
$0
operating Margin
0%
total Assets
$0
total Debt
$0
net Income
$0
eps
$0
gross Margin
0%
cash Position
$0
revenue Growth
+0%

Executive Compensation

NameTitleTotal Compensation
Not DisclosedNot Disclosed$0

Key Numbers

Key Players & Entities

FAQ

What are the key proposals for stockholders at the REVIVA PHARMACEUTICALS Annual Meeting?

Stockholders of REVIVA PHARMACEUTICALS will vote on electing five director nominees, ratifying Baker Tilly US, LLP as the independent auditor for 2025, approving executive compensation on an advisory basis, increasing authorized common stock from 315,000,000 to 515,000,000, and adopting a reverse stock split ranging from 1-for-2 to 1-for-20.

Why is REVIVA PHARMACEUTICALS proposing to increase its authorized shares?

REVIVA PHARMACEUTICALS is proposing to increase its authorized shares of common stock from 315,000,000 to 515,000,000 to provide the company with greater flexibility for future capital-raising activities, potential strategic transactions, or to maintain compliance with exchange listing requirements, as stated in the DEF 14A filing.

What is the proposed range for the reverse stock split for REVIVA PHARMACEUTICALS?

The proposed reverse stock split for REVIVA PHARMACEUTICALS has a ratio ranging from one-for-two (1:2) to one-for-twenty (1:20). The Board of Directors will have the discretion to determine the specific ratio and implementation date prior to December 31, 2026.

When and where will the REVIVA PHARMACEUTICALS Annual Meeting be held?

The REVIVA PHARMACEUTICALS Annual Meeting will be held virtually via the Internet on Thursday, December 18, 2025, at 11:00 a.m. Pacific Time. Stockholders can access the meeting at www.virtualshareholdermeeting.com/RVPH2025 using their 16-digit control number.

Who is eligible to vote at the REVIVA PHARMACEUTICALS Annual Meeting?

Only stockholders of record at the close of business on the record date, October 21, 2025, are entitled to receive the E-Proxy Notice and to vote the shares of common stock they held on that date at the Annual Meeting.

What is the Board of Directors' recommendation on the proposals for REVIVA PHARMACEUTICALS?

The Board of Directors of REVIVA PHARMACEUTICALS recommends a 'FOR' vote on all six proposals: the Director Election Proposal, Auditor Ratification Proposal, Say-on-Pay Proposal, Increase in Authorized Proposal, Reverse Stock Split Proposal, and Adjournment Proposal, believing them to be in the best interests of the Company and its stockholders.

What are the implications of a reverse stock split for REVIVA PHARMACEUTICALS stockholders?

A reverse stock split for REVIVA PHARMACEUTICALS would reduce the number of outstanding shares and proportionally increase the stock price per share. While it doesn't change the total value of a stockholder's investment immediately, it's often used to meet minimum bid price requirements for stock exchanges like NASDAQ and can make the stock appear more attractive to institutional investors.

How does REVIVA PHARMACEUTICALS handle executive compensation?

REVIVA PHARMACEUTICALS' executive compensation is detailed in the 2024 Summary Compensation Table within the proxy statement, covering named executive officers. Stockholders will have an advisory vote on this compensation, and the company also outlines employment agreements and outstanding equity awards at fiscal year-end 2024.

What is the role of Baker Tilly US, LLP for REVIVA PHARMACEUTICALS?

Baker Tilly US, LLP is the independent registered public accounting firm whose appointment for the year ending December 31, 2025, REVIVA PHARMACEUTICALS' stockholders are asked to ratify. Their role involves auditing the company's financial statements to ensure accuracy and compliance.

What is a 'broker non-vote' and how does it affect REVIVA PHARMACEUTICALS' proposals?

A 'broker non-vote' occurs when a broker holding shares in 'street name' does not receive voting instructions from the beneficial owner for a 'non-routine' matter. For REVIVA PHARMACEUTICALS, the Director Election Proposal is likely non-routine, meaning broker non-votes will not affect its outcome. The Auditor Ratification Proposal is routine, so no broker non-votes are expected for it.

Industry Context

Reviva Pharmaceuticals Holdings, Inc. operates in the highly competitive and capital-intensive biotechnology and pharmaceutical sector. This industry is characterized by long development cycles, significant research and development costs, and stringent regulatory hurdles. Companies often rely on strategic financing and potential partnerships to advance drug candidates through clinical trials and towards commercialization.

Regulatory Implications

As a pharmaceutical company, RVPH is subject to extensive regulation by bodies like the FDA. Compliance with these regulations is critical for drug development and market approval. The proposed increase in authorized shares and potential reverse stock split may also be influenced by NASDAQ listing requirements, which often have minimum share price thresholds.

What Investors Should Do

  1. Review the proposals regarding the increase in authorized shares and the reverse stock split, considering the potential impact on share dilution and stock price.
  2. Evaluate the election of director nominees based on their experience and alignment with the company's strategic direction.
  3. Consider the ratification of Baker Tilly US, LLP as the independent auditor, ensuring confidence in the company's financial reporting.
  4. Understand the advisory vote on executive compensation to gauge alignment between executive pay and company performance.

Key Dates

Glossary

DEF 14A
A proxy statement filing with the SEC that provides detailed information about matters to be voted on at a company's annual meeting. (This document is the primary source of information for stockholders to understand the company's proposals and make informed voting decisions.)
Named Executive Officers (NEOs)
The top executive officers of a company, typically the CEO, CFO, and other highest-paid executives, whose compensation is detailed in the proxy statement. (Provides transparency into the compensation packages of the company's leadership.)
Independent Registered Public Accounting Firm
An external audit firm hired by a company to conduct an independent audit of its financial statements. (Ratifying the auditor ensures the integrity and reliability of the company's financial reporting.)
Reverse Stock Split
A corporate action where a company reduces the total number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (RVPH is considering this to potentially increase its stock price and meet exchange listing requirements.)
Authorized Shares
The maximum number of shares of stock that a corporation is legally permitted to issue, as specified in its charter. (RVPH is proposing to increase authorized shares to provide financial flexibility for future capital raises or acquisitions.)
E-Proxy Notice
An electronic notification sent to stockholders informing them that proxy materials are available online. (The primary method RVPH is using to distribute its proxy materials for the annual meeting.)

Year-Over-Year Comparison

This filing indicates a significant strategic shift for Reviva Pharmaceuticals Holdings, Inc. compared to previous periods, focusing on financial restructuring and capital flexibility. The key proposals to increase authorized shares by 63.5% and implement a reverse stock split suggest a proactive approach to managing its stock price and potentially meeting exchange listing requirements, which may not have been as prominent in prior filings.

Filing Stats: 4,841 words · 19 min read · ~16 pages · Grade level 14.2 · Accepted 2025-11-04 16:16:24

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 16 2024 Summary Compensation Table 16 Employment Agreements with Our Named Executive Officers 17 Outstanding Equity Awards at Fiscal Year End - 2024 19 PAY VERUS PERFORMANCE 20 DIRECTOR COMPENSATION 23 Director Compensation 23 Non-Employee Director Compensation Policy 23 Indemnification Agreements 24 EQUITY COMPENSATION PLAN INFORMATION 25 2020 Equity Incentive Plan 25 2006 Equity Incentive Plan 25 REPORT OF THE AUDIT COMMITTEE 26

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 27 TRANSACTIONS WITH RELATED PERSONS 29 PROPOSAL 2 31 PROPOSAL 3 34 PROPOSAL 4 35 PROPOSAL 5 37 PROPOSAL 6 45 STOCKHOLDER PROPOSALS 46 ANNUAL REPORT 46 HOUSEHOLDING OF ANNUAL MEETING MATERIALS 46 OTHER MATTERS 47 i REVIVA PHARMACEUTICALS HOLDINGS, INC. 10080 N WOLFE ROAD, SUITE SW3-200 CUPERTINO, CA 95014 PROXY STATEMENT This proxy statement contains information related to the Annual Meeting of Stockholders (the "Annual Meeting") of Reviva Pharmaceuticals Holdings, Inc. (the "Company") to be held on Thursday, December 18, 2025 at 11:00 a.m. Pacific Time. We are planning to hold the Annual Meeting virtually via the Internet, or at such other time and place to which the Annual Meeting may be adjourned or postponed. In order to attend our Annual Meeting, you must log in to www.virtualshareholdermeeting.com/RVPH2025 using the 16-digit control number included on your Notice of Internet Availability of Proxy Materials (the "E-Proxy Notice" or the "Notice") (or on your proxy card, if you requested delivery of paper materials). Proxies for the Annual Meeting are being solicited by the Board of Directors of the Company (the "Board"). An E-Proxy Notice is first being sent to stockholders, and this proxy statement is first being made available to stockholders, on or about November 4, 2025. A list of record holders of the Company's common stock entitled to vote at the Annual Meeting will be available for examination by any stockholder, for any purpose germane to the Annual Meeting, at our principal offices at 10080 N Wolfe Road, Suite SW3-200, Cupertino, CA 95014, during normal business hours for ten days prior to the Annual Meeting and available during the Annual Meeting. IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER 18, 2025: Our proxy materials including our Notice of Internet Availability

View on Read The Filing